Nebenwirkungen · Hemlibra
Hemlibra 30 mg/mL solution for injection Hemlibra 150 mg/mL solution for injection · Abschnitt 4.8 · PDF-Seite 12
HOS-138570 · Präparat HOS-098208
In the pooled phase III clinical studies with Hemlibra, development of neutralising anti-emicizumab antibodies associated with decreasing emicizumab concentration was uncommon (see section 5.1). One patient, who developed neutralising anti-emicizumab antibodies with decreasing emicizumab concentration, experienced loss of efficacy (manifest as breakthrough bleeding) after five weeks of treatment and later discontinued Hemlibra treatment (see sections 4.4 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T14:44:00Z · SHA-256 a8b20be3c4cbbb534d4c89f4bc9fce14de5f500ee77b5005f9098554ba0096ef · Passage a2459413fb329e4e3a098ff76d2361cce0584d5a96de0947a8f18e4b4e496ec2 · Zeichen 7605–8073 im Abschnitt